# A Prospective Study Comparing Ranibizumab Plus Dexamethasone Combination Therapy Versus Ranibizumab Monotherapy for Wet AMD

> **NCT00793923** · PHASE1,PHASE2 · COMPLETED · sponsor: **Subhransu K. Ray, M.D., Ph.D.** · enrollment: 40 (actual)

## Conditions studied

- Exudative Age-Related Macular Degeneration

## Interventions

- **DRUG:** ranibizumab and dexamethasone
- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT00793923
- **Lead sponsor:** Subhransu K. Ray, M.D., Ph.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2012-01
- **Final completion:** 2012-12
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2012-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00793923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00793923, "A Prospective Study Comparing Ranibizumab Plus Dexamethasone Combination Therapy Versus Ranibizumab Monotherapy for Wet AMD". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00793923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*